



PRESS RELEASE

Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.

Cambridge UK, January 2013 - Antitope Ltd., UK ("Antitope") today announced a Research Agreement with NeuroPhage Pharmaceuticals, Inc., USA ("NeuroPhage") for the generation of a therapeutic protein with reduced immunogenicity. Under the Agreement, Antitope will apply its proprietary Composite Protein™ deimmunisation technology to a next generation treatment for neurodegenerative diseases.

"We are delighted to be working with such an innovative company as NeuroPhage," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "This partnership utilizes Antitope's expertise in engineering non-immunogenic proteins to complement NeuroPhage's innovations in developing novel therapeutics based on the clearance of pathologic protein aggregates."

About Antitope

Antitope Ltd. is a privately-held Cambridge, UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope's proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of humanised antibodies and therapeutic proteins devoid of T cell epitopes. Antitope's proprietary Composite CHO™ and cell line development technologies result in the generation of high yielding manufacturing cell lines suitable for transfer to CMOs and GMP manufacturing. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For more information, please visit www.antitope.co.uk or contact:

Antitope Ltd.
Dr Neil Butt, Business Development Director
Tel: +44 (0)1223 496190
Email: info@antitope.co.uk

About NeuroPhage Pharmaceuticals, Inc.

NeuroPhage is a biotechnology company focusing on a unique disease-modifying approach for treating protein aggregation diseases. NeuroPhage was founded in 2007 by a team based in Cambridge, MA along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.

For more information, please visit www.neurophage.com or contact: info@neurophage.com